BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.

Darzalex added another string to its bow, while Kisqali’s early use has been delayed.

More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.

The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.

The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.